Zhiyuan's Methyl Beta cyclodextrin obtained the CDE excipient registration number

On July 29, 2021, the "methyl beta cyclodextrin" produced by Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. was successfully registered in the Center for Drug Evaluation (CDE) of the State Drug Administration, CDE registration number: F20210000272. As the first professional cyclodextrin manufacturer in China to register methyl beta cyclodextrin in CDE, Zhiyuan Biotech has been practicing the corporate mission of "Exploring the unlimited applications of cyclodextrin in human activities". Promote the application of cyclodextrin in the field of human medical care and health. This record registration successfully reflects Zhiyuans high technical level and excellent product quality. It also clears obstacles for in-depth cooperation in formulation research and development, and can tangibly help formulation manufacturers solve difficulties and participate in new drug research and development.

Methyl beta cyclodextrin is one of the cyclodextrin derivatives that have been widely studied and used. Easily soluble in water and soluble in organic solvents. It can improve the solubility and bioavailability of drugs in medicine, increase the efficacy of drugs or reduce the dosage, adjust or control the release rate of drugs, reduce drug side effects, and enhance drug stability It is especially effective for increasing water solubility of oil-soluble molecules.
 As a professional production plant in the field of cyclodextrin pharmaceutical excipients, the company has established domestic advanced GMP standard workshops, quality inspection centers, and a complete GMP management system. Now the methyl beta cyclodextrin has obtained the CDE registration number: F20210000272, and the association review of pharmaceutical preparation enterprises is welcome. At the same time, Zhiyuan Bio will continue to provide more efficient, high-quality, cost-competitive and flexible products and drug solubility solutions to help customers achieve more development and production of original research drugs and innovative drugs, and promote independent innovation in China's pharmaceutical industry pace.